Dimerix's (ASX:DXB) potential successful interim readout could allow accelerated approval of DMX-200 in Focal Segmental Glomerulosclerosis, enabling US sales to start in the second half of calendar 2026, said Euroz Hartleys in a Monday note.
The research firm noted that the company's US entry would significantly reduce its regulatory risk, as under its US licensing deal with Amicus Therapeutics, success might unlock up to AU$119 million in development milestone payments, equivalent to around AU$0.20 per share in cash.
The research firm also noted that an additional AU$709 million could be earned in commercial milestone payments, and it would also receive tiered royalties in the low-teen to low-twenties percentage range based on US net sales.
Euroz Hartleys has maintained its speculative buy recommendation with a price target of AU$1.68.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。